Assembly Biosciences (NASDAQ:ASMB) Posts Earnings Results, Beats Expectations By $0.11 EPS

Key Points

• Assembly Biosciences beat earnings expectations for the quarter, reporting EPS of -$0.54 versus analysts’ estimate of -$0.65, a beat of $0.11 per share.
• Revenue came in below forecasts at $8.21 million, compared with the Street’s expectation of $9.27 million.
• Wall Street remains cautiously positive: the stock has a consensus rating of Moderate Buy with a target price of $42.75, though some analysts still rate it a sell.

Assembly Biosciences (NASDAQ:ASMB - Get Free Report) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.65) by $0.11, Zacks reports. Assembly Biosciences had a negative return on equity of 4.70% and a negative net margin of 8.98%.The company had revenue of $8.21 million for the quarter, compared to analyst estimates of $9.27 million.

Assembly Biosciences Price Performance

Assembly Biosciences stock traded down $1.19 during midday trading on Friday, hitting $29.74. 143,418 shares of the company's stock were exchanged, compared to its average volume of 141,040. Assembly Biosciences has a 52-week low of $11.64 and a 52-week high of $39.71. The stock has a 50-day moving average price of $28.67 and a two-hundred day moving average price of $30.55.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Assembly Biosciences in a research note on Monday, April 20th. Guggenheim boosted their target price on Assembly Biosciences from $39.00 to $43.00 and gave the stock a "buy" rating in a research report on Monday, April 6th. Wall Street Zen upgraded Assembly Biosciences from a "buy" rating to a "strong-buy" rating in a research report on Sunday, March 29th. Finally, HC Wainwright restated a "buy" rating and set a $50.00 target price on shares of Assembly Biosciences in a research report on Monday. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $42.75.

Hedge Funds Weigh In On Assembly Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of ASMB. Acadian Asset Management LLC boosted its holdings in shares of Assembly Biosciences by 42.1% in the 1st quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company's stock worth $219,000 after purchasing an additional 6,823 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Assembly Biosciences by 6.9% in the 2nd quarter. Geode Capital Management LLC now owns 51,015 shares of the biopharmaceutical company's stock worth $925,000 after purchasing an additional 3,312 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Assembly Biosciences by 97.8% in the 3rd quarter. Vanguard Group Inc. now owns 502,112 shares of the biopharmaceutical company's stock worth $12,854,000 after purchasing an additional 248,287 shares in the last quarter. ADAR1 Capital Management LLC bought a new stake in shares of Assembly Biosciences in the 3rd quarter valued at about $485,000. Finally, Schonfeld Strategic Advisors LLC bought a new stake in shares of Assembly Biosciences in the 3rd quarter valued at about $3,120,000. 19.92% of the stock is currently owned by hedge funds and other institutional investors.

About Assembly Biosciences

Assembly Biosciences, Inc NASDAQ: ASMB is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company's core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly's research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company's lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.